Characteristics of mature aggressive B-cell lymphomas analyzed by immunohistochemistry.

<p>Characteristics of mature aggressive B-cell lymphomas analyzed by immunohistochemistry.</p

Immunohistochemical analysis in a case of follicular lymphoma and its transformed counterpart.

<p>Sections from a follicular lymphoma (a) that subsequently acquired a <i>c-myc</i> translocation and transformed into a DLBCL (b) were analyzed for EBI3 expression by immunohistochemistry. The bar represents 50 µm.</p

Immunohistochemical analysis of EBI3 expression in BL, BL/DLBCL and DLBCL.

<p>Sections from a case of BL (a), 2 cases of BL/DLBCL (b, c), and 2 cases of DLBCL (d, e) with or without <i>c-myc</i> translocation as indicated on each figure, were analyzed for EBI3 expression by immunohistochemistry. An inverse correlation between the presence of <i>c-myc</i> translocation and the positivity for EBI3 in tumoral cells was observed. Each picture is shown at the same magnification. The bar shown on (c) represents 50 µm.</p

<i>In vitro</i> effect of c-myc overexpression on <i>EBI3</i> expression level.

<p>Karpas 1106 cell line was transfected with a GFP reporter plasmid together with c-myc-ER expression vector or a control vector and cultured for various times in the absence or presence of 4-OHT. <i>EBI3</i> expression in GFP-positive cells isolated from vector control transfected cells (Col) or c-myc-ER transfected cells (c-myc-ER) was analyzed by RTqPCR. In (A), transfected cells were cultured for 20 hours in the presence of 4-OHT (200 nM). Data are expressed as mean ± SEM from 3 independent transfections. p value is indicated. In (B), cells were cultured for 20 hours in the absence or presence of 4-OHT (200 nM). In (C), cells were cultured with increasing concentrations of 4-OHT. The expression of <i>EBI3</i> in c-myc-ER transfected cells relative to that measured in control tranfected cells is represented. The percentage of decrease is indicated. A higher concentration of 4-OHT (1 µM) did not result in higher repression of <i>EBI3</i> expression (not shown). In (D), 4-OHT was added to the transfected cells for the last 16, 24 or 40 h of the culture. In (B)–(D), a representative experiment is shown.</p

Analysis of <i>EBI3</i> gene expression according to the presence or absence of <i>c-myc</i> translocation.

<p>Individual data for <i>EBI3</i> and <i>c-myc</i> were retrieved from GSE4475 and GSE10172 series <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0024617#pone.0024617-Hummel1" target="_blank">[8]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0024617#pone.0024617-Klapper1" target="_blank">[21]</a>. On (A), the expression of <i>EBI3</i> and of <i>c-myc</i> was analyzed according to the presence or not of <i>c-myc</i> translocations involving an Ig locus (Ig-myc) or not (non-Ig-myc). « others » designated lymphomas other than mBL, ie lymphomas classifed as non-mBL and lymphomas that could not be classified as mBL or non-mBL. On (B), <i>EBI3</i> expression among all lymphomas other than mBL is represented according to that of <i>c-myc</i>. On (C), <i>EBI3</i> expression among lymphomas that had initially received a pathological diagnosis of BL/DLBCL is shown according to that of <i>c-myc</i>. p values are indicated. NS: not significant.</p

Figure 1

<p><b>A & B</b>: Rare or no (arrows) H/RS cells stained with CD20 in refractory cHL (<b>A</b>) compared to the overexpression of CD20 on H/RS cells in a responder cHL (arrows) (<b>B</b>) (original magnification ×400). <b>C & D</b>: Numerous H/RS cells stained with bcl2 in a refractory cHL (arrows)(<b>C</b>) comparing to rare cells in a responder case (arrow)(<b>D</b>) (original magnification ×400). <b>E & F</b>: TiA1 expressed on numerous small lymphocytes in a refractory cHL (arrows) (<b>E</b>) and less frequent cells stained with this antibody in a responder cHL (arrows) (<b>F</b>) (original magnification ×400). <b>G & H</b>: c-kit stained frequent mast cells in a refractory cHL (arrows) (<b>G</b>) compared to rare mast cells expressing c-kit in a responder cHL (arrows) (<b>H</b>) (original magnification ×400).</p

Characteristics of patients & IHC markers (univariate analysis).

<p><b>Legends</b>: pts = patients sbtype = subtype L = lymphocytes MC = mast cells nber = number IHC:immunohistochemical CV: continuous variable HRS: Hodgkin and Reed Sternberg cells.</p

Treatments.

<p>m: month. AZA: azathiopurin. 6MP: 6 mercaptopurin. clinical response (+ or-) / mucosal effect (+/-)</p><p>Treatments.</p

Phenotype of lamina propria intestinal lymphocytes.

<p>Phenotype of lamina propria intestinal lymphocytes.</p